Replies to post #160866 on Biotech Values

[DewDiligence]

PTLA—Is ~$500M (#msg-87681951 ) too steep?

I’m not sure yet. Have to read the S-1 papers.

[DewDiligence]

PTLA reports top-line phase-2 data for PRT4445 as Eliquis antidote:

http://finance.yahoo.com/news/portola-announces-factor-xa-inhibitor-120000977.html

Analysis of anticoagulation markers and plasma concentration levels of Eliquis in blood samples taken from the subjects indicates that PRT4445 produces a rapid, sustained and dose-related reversal of the anticoagulant activity of Eliquis. In addition, no serious adverse events were reported. Additional details will be presented at an upcoming medical conference.

These data are well-timed vis-à-vis PTLA’s plans to IPO.